{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T23:06:34Z","timestamp":1774566394150,"version":"3.50.1"},"reference-count":8,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bevacizumab, a VEGF-A inhibitor widely used in ovarian cancer, is associated with kidney adverse effects ranging from mild proteinuria to thrombotic microangiopathy (TMA). However, the longitudinal course, reversibility, and spectrum of kidney-limited injury remain under-characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case report<\/jats:title>\n                    <jats:p>We describe three patients with ovarian cancer who developed proteinuria during prolonged bevacizumab therapy, including one with biopsy-proven kidney-limited glomerular microangiopathy. Proteinuria emerged after 6 to 12 months of exposure in all cases. Kidney function remained preserved throughout treatment. All three patients discontinued bevacizumab, after which proteinuria consistently improved. Two patients experienced complete resolution within 3 to 6 months, and one showed marked reduction to dipstick 1 plus by three months. Kidney biopsy in one case revealed double-contour basement membrane changes and subendothelial electron-dense deposits, confirming kidney-limited TMA without systemic microangiopathic findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These cases illustrate the characteristic time course of bevacizumab-induced kidney toxicity, highlight the reversibility of proteinuria following drug discontinuation, and demonstrate that bevacizumab can induce kidney-limited TMA in the absence of systemic microangiopathic features. Multidisciplinary management is essential to balance oncologic benefit with kidney safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1752830","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:16:20Z","timestamp":1769145380000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Glomerular microangiopathy and reversible renal toxicity during prolonged bevacizumab therapy in ovarian cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jungheon","family":"Kwon","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Gyeongsan Joongang Hospital","place":["Daegu, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Misun","family":"Choe","sequence":"additional","affiliation":[{"name":"Department of Pathology, Keimyung University School of Medicine","place":["Daegu, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Hyuk","family":"Paek","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Keimyung University School of Medicine","place":["Daegu, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woo Yeong","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Keimyung University School of Medicine","place":["Daegu, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyubok","family":"Jin","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Keimyung University School of Medicine","place":["Daegu, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seungyeup","family":"Han","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Keimyung University School of Medicine","place":["Daegu, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Heum","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Keimyung University School of Medicine","place":["Daegu, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaerim","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Internal Medicine, Keimyung University School of Medicine","place":["Daegu, Republic of Korea"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ogc.2018.09.009","article-title":"Chemotherapy, biologic, and immunotherapy breakthroughs in cancer care","volume":"46","author":"Rojas","year":"2019","journal-title":"Obstet Gynecol Clin North Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2019.08.008","article-title":"Personalized medicine in gynecologic cancer: fact or fiction","volume":"29","author":"Corey","year":"2020","journal-title":"Surg Oncol Clin N Am"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6911","DOI":"10.3390\/ijms23136911","article-title":"The utilization of bevacizumab in patients with advanced ovarian cancer: A systematic review of the mechanisms and effects","volume":"23","author":"Mao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2010020167","article-title":"Bevacizumab increases risk for severe proteinuria in cancer patients","volume":"21","author":"Wu","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"155824","DOI":"10.1016\/j.prp.2025.155824","article-title":"Clinicopathological analysis of anti-VEGF drug-associated renal thrombotic microangiopathy: A case series and review of the literature","volume":"266","author":"Han","year":"2025","journal-title":"Pathol Res Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s10147-024-02474-7","article-title":"Proteinuria frequency and subsequent renal dysfunction in bevacizumab-treated patients: a single center, retrospective, observational study","volume":"29","author":"Kataoka","year":"2024","journal-title":"Int J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1681\/ASN.2018080853","article-title":"Therapeutic inhibition of VEGF signaling and associated nephrotoxicities","volume":"30","author":"Estrada","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e940906","DOI":"10.12659\/AJCR.940906","article-title":"Bevacizumab-associated thrombotic microangiopathy treated with eculizumab: A case report","volume":"24","author":"Padilha","year":"2023","journal-title":"Am J Case Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1752830\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:16:21Z","timestamp":1769145381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1752830\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":8,"alternative-id":["10.3389\/fonc.2026.1752830"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1752830","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"article-number":"1752830"}}